Analytik Jena AG (ETR:AJA) will release the fourth quarter earnings for 2008 on Thursday, December 17. The company has not scheduled a conference call to review the financial results. The financial results will be released on the company’s Investor News site at www.analytik-jena.de/en/site/Investor-News__3877/. For more information regarding the earnings release, contact Dana Schmidt at +49 (0) 36 41 77-92 81, or ir@analytik-jena.com.
Top Best Penny Stocks, a leading financial publication, is pleased to alert investors of stocks on the move. Sign up for our Free Stock Newsletter.
Analytik Jena AG is a Germany-based company operating in the field of optical spectroscopy and elemental analytics. The Company divides its operations in two segments: Instrument and Project. The Instrument business segment is divided into three business units: analytical solutions, bio solutions and optical solutions. The Instrument business unit offers analytical, bioanalytical and optical instruments, consumables and reagents, and laboratory data systems. The Project business segment operates in the planning and implementation of complex medical research, teaching and life science projects. The Company’s subsidiaries include AJ Blomesystem GmbH, AJ Cybertron Gesellschaft fuer Laborautomationssysteme mbH, AJ eBiochip GmbH, AJ Innuscreen GmbH, AJ IDC Geraeteentwicklungsgesellschaft mbH and AJ Roboscreen GmbH, among others. Analytik Jena AG has operations in Germany, the Netherlands, the United States, China and Japan.
Sign up for Top Best Penny Stocks' free newsletter. To subscribe, enter your e-mail address into the frame at the bottom of this press release or visit our website.
Follow us on Twitter: http://www.Twitter.com/topbestps
About Us
Top Best Penny Stocks is a leading stock web site that allows investors and interested parties to research stocks that are on the move. We also track small cap companies that are on the brink of a financial breakout. To feature a company on our web site please contact us at the email listed below.
Please click here to read the full disclaimer.
